Calciphylaxis-as a drug induced adverse event

Area of Science:

• Nephrology
• Dermatology
• Vascular Medicine

Background:

• Calciphylaxis is a rare, severe condition with high mortality, characterized by painful ischemic skin lesions and vascular calcification.
• It predominantly affects patients with end-stage renal disease (ESRD), often linked to multiple prescribed medications.
• Medication use is a significant, modifiable risk factor in calciphylaxis development.

Purpose of the Study:

• To provide an overview of calciphylaxis.
• To examine how therapeutic agents influence calcification and thrombosis in calciphylaxis.
• To highlight medication management as a key treatment strategy.

Main Methods:

• Review of existing literature on calciphylaxis.
• Focus on the role of specific medications in disease pathogenesis.
• Analysis of multi-modal treatment approaches.

Main Results:

• Certain medications (warfarin, active vitamin D, calcium supplements, iron) are implicated in calciphylaxis.
• Discontinuation of contributing medications is a cornerstone of treatment.
• Multi-modal treatment includes prevention, risk factor management, wound care, and supportive therapies.

Conclusions:

• Calciphylaxis necessitates a comprehensive treatment strategy.
• Careful medication review and discontinuation are vital, especially in ESRD patients.
• Managing modifiable risk factors, particularly medication use, is essential for improving outcomes in calciphylaxis.